Diversified Healthcare Trust Announces Sale of Additional 10% Equity Interest in Life Science Property Located in Boston Seaport District

Rhea-AI Summary

Diversified Healthcare Trust (Nasdaq: DHC) has announced the sale of a 10% equity interest in its life science complex located in Boston for approximately $108 million. This transaction values the property at $1.7 billion after accounting for $620 million of existing debt. DHC intends to utilize the proceeds for capital expenditures, debt reduction, and general business purposes. The complex is nearly fully leased to Vertex Pharmaceuticals and reflects DHC's significant healthcare property portfolio valued at $6.8 billion.

Positive

• Generated approximately $108 million from the sale of a 10% equity interest.
• Property valuation set at approximately $1.7 billion, indicating strong asset value.
• Approx. 95% leased to Vertex Pharmaceuticals, ensuring stable income.

Negative

• Existing secured debt of $620 million could impact financial flexibility.
• Uncertainties regarding COVID-19 may affect future liquidity and capital expenditure outcomes.

DHC Receives Proceeds of Approximately $108 Million

NEWTON, Mass.--(BUSINESS WIRE)-- Diversified Healthcare Trust (Nasdaq: DHC) today announced that it has sold an additional 10% equity interest in the two building life science complex located at 11 Fan Pier and 50 Northern Avenue in Boston, MA. DHC sold the interest to an existing joint venture partner for a purchase price of approximately $108 million. The purchasing partner now owns a 45% interest in the joint venture, another partner continues to own a 45% equity interest, and DHC owns the remaining 10% equity interest. The purchase price for the 10% equity interest is based on a property valuation of $1.7 billion, less the $620 million of existing secured debt on the property.

The property was acquired by DHC in May 2014 for $1.1 billion and consists of two 15-story, class A LEED® Gold Certified life science buildings located in Boston’s Seaport District. The two buildings are approximately 95% leased to Vertex Pharmaceuticals, Inc., and include 1.1 million rentable square feet of lab, corporate office and street level retail space.

DHC expects to use the proceeds from this transaction to fund capital expenditures, to reduce outstanding indebtedness and for other general business purposes.

Diversified Healthcare Trust (Nasdaq: DHC) is a real estate investment trust (REIT) that owns approximately $6.8 billion of high-quality healthcare properties located in 36 states and Washington, D.C. DHC seeks diversification across the health services spectrum: by care delivery and practice type, by scientific research disciplines and by property type and location. DHC’s life science and medical office portfolio includes over 100 properties totaling approximately nine million square feet and is occupied by almost 500 tenants. DHC’s senior living portfolio contains over 27,500 senior living units. DHC is managed by The RMR Group (Nasdaq: RMR), a leading U.S. alternative asset management company with more than $37 billion in assets under management and more than 35 years of institutional experience in buying, selling, financing and operating commercial real estate. DHC is headquartered in Newton, MA. To learn more about DHC, visit www.dhcreit.com.

The joint venture and DHC are managed by RMR. RMR is responsible for providing all aspects of business and property management services for nearly 1,400 properties with approximately 116 million square feet of commercial office, industrial, medical office, life science and retail space.

WARNING REGARDING FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Also, whenever DHC uses words such as “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “will”, “may” and negatives or derivatives of these or similar expressions, DHC is making forward-looking statements. These forward-looking statements are based upon DHC’s present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by DHC’s forward-looking statements as a result of various factors. Forward-looking statements involve known and unknown risks, uncertainties and other factors, some of which are beyond DHC's control. For example:

• This press release states that DHC expects to use the proceeds from this transaction to fund capital expenditures, to reduce outstanding indebtedness and for other general business purposes. This statement may imply that DHC will be able to sustain sufficient liquidity and reduce its overall leverage. However, if the duration and severity of the COVID-19 pandemic and its impacts on DHC and its managers and tenants significantly worsen for a sustained period, DHC may be required to utilize all or a significant portion of its cash and cash equivalents to fund its business and operations, which may reduce or eliminate any balance sheet liquidity achieved by this transaction. Further, DHC’s capital expenditures may be delayed or may cost more than expected due to supply chain disruptions, market inflation, labor shortages or other conditions, and any capital investments DHC makes at its properties may not achieve expected results and DHC’s properties may not be competitive despite these capital investments.

The information contained in DHC’s filings with the Securities and Exchange Commission, or SEC, including under “Risk Factors” in DHC’s periodic reports, or incorporated therein, identifies other important factors that could cause DHC’s actual results to differ materially from those stated in or implied by DHC’s forward-looking statements. DHC’s filings with the SEC are available on the SEC's website at www.sec.gov.

You should not place undue reliance upon forward-looking statements.

Except as required by law, DHC does not intend to update or change any forward-looking statements as a result of new information, future events or otherwise.

A Maryland Real Estate Investment Trust with transferable shares of beneficial interest listed on the Nasdaq.
No shareholder, Trustee or officer is personally liable for any act or obligation of the Trust.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005900/en/

Michael Kodesch, Director, Investor Relations

(617) 796-8234

www.dhcreit.com

Source: Diversified Healthcare Trust

FAQ

What recent transaction did DHC announce involving its Boston properties?

DHC announced the sale of a 10% equity interest in its life science complex in Boston for approximately $108 million.

What is the valuation of the property involved in DHC's recent sale?

The property was valued at approximately $1.7 billion, accounting for existing secured debt of $620 million.

How does DHC plan to use the proceeds from the recent sale?

DHC expects to use the proceeds for capital expenditures, reducing outstanding indebtedness, and for other general business purposes.

What percentage of the Boston property is leased to Vertex Pharmaceuticals?

The property is approximately 95% leased to Vertex Pharmaceuticals.

What is the size and scope of DHC's overall property portfolio?

DHC owns approximately $6.8 billion in healthcare properties located in 36 states, including over 100 life science and medical office properties.